Capricor Therapeutics logo

Capricor Therapeutics

CAPR | NASDAQ
Chart Builder DCF Calculator
$8.30
-$1.23 (-12.91%)
At close: Nov 16, 2026, 4:00 PM ET
$8.17
-$0.13 (-1.57%)
After-hours: Nov 16, 2026, 7:56 PM ET
-12.91%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
23.6
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #955/1021 (Top 94%)

Key Statistics

Market Data

Market Cap $480.67M
1D Range
8.19 9.35
52W Range
3.85 35.34

Valuation (TTM)

PE -3.14
PB 2.29
EV/EBITDA 0.32

Valuation (NTM)

Forward PE 33.15
Forward PEG -0.31
Price Target $7.00
Loading financial charts...

Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (...

Sector Healthcare
Industry Biotechnology
Employees 231
IPO Date Feb 13, 2007
Fiscal Year January - December

Latest News

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

4 months ago · benzinga.com

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli

4 months ago · benzinga.com

QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

4 months ago · globenewswire.com

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy

4 months ago · proactiveinvestors.com

Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents

4 months ago · benzinga.com

Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
FDA staff flags concerns for Capricor's Duchenne heart disease therapy

4 months ago · reuters.com

FDA staff flags concerns for Capricor's Duchenne heart disease therapy
What's Going On With Capricor Therapeutics Stock On Friday?

5 months ago · benzinga.com

What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

5 months ago · globenewswire.com

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Caprock Announces Closing of Private Placement

5 months ago · newsfilecorp.com

Caprock Announces Closing of Private Placement
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

5 months ago · newsfilecorp.com

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

Earnings

Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$7.00
Downside
-15.66%
Buy (6)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.